Biotech


  • Biogen
    Image attribution tooltip
    Permission granted by Biogen
    Image attribution tooltip

    Biogen, looking to diversify, acquires immune drugmaker HI-Bio for $1.15B

    The deal, only Biogen’s third since the start of 2018, is a sign the company is open to branching out beyond the neurological drugs that have long been its focus. 

    By Kristin Jensen • May 22, 2024
  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Daniel Tadevosyan via Getty Images
    Image attribution tooltip
    News roundup

    Regeneron faces new biosimilar threats; an AI biotech lays off staff

    Today’s rundown also includes news of an expanded partnership for Boehringer Ingelheim and updates to emerging medicines from GSK and Bristol Myers. 

    By BioPharma Dive staff • May 22, 2024
  • Transmission electron micrograph of SARS-CoV-2 virus particles, isolated from a patient. Explore the Trendline
    Image attribution tooltip
    National Institute of Allergy and Infectious Diseases. (2020). "Novel Coronavirus SARS-CoV-2" [Micrograph]. Retrieved from Flickr.
    Image attribution tooltip
    Trendline

    COVID-19 vaccines

    The urgency of the pandemic’s first two years is giving way to questions of how to sustain public health responses and prepare for what could come next. In the U.S., health officials are urging booster shots and preparing for private sector distribution of vaccines.

    By BioPharma Dive staff
  • A portrait of Philip Larsen, CEO of SixPeaks Bio AG.
    Image attribution tooltip
    Permission granted by SixPeaks Bio AG
    Image attribution tooltip
    Obesity drugs

    SixPeaks, a new obesity biotech, starts up with an option to sell to AstraZeneca

    AstraZeneca has an exclusive chance to buy the startup, which is developing a muscle-protecting weight loss medicine, within the next two years.

    By May 22, 2024
  • A white sign with the word Lilly written in red stands outside of an office.
    Image attribution tooltip
    Scott Olson via Getty Images
    Image attribution tooltip

    Lilly partners with Aktis, deepening radiopharma investment

    The collaboration, which gives Lilly access to Aktis’ technology in return for $60 million, adds to a flurry of dealmaking in the radiopharma field.

    By May 21, 2024
  • A person works in a laboratory at AltruBio.
    Image attribution tooltip
    Permission granted by AltruBio
    Image attribution tooltip
    Emerging biotech

    AltruBio lands up to $225M after shift to immune drug research

    Since pivoting from oncology, the startup has raised close to $300 million and advanced an ulcerative colitis drug into mid-stage testing.

    By May 21, 2024
  • A headshot of Cyrus Mozayeni, CEO of Pheon Therapeutics.
    Image attribution tooltip
    Permission granted by Pheon Therapeutics
    Image attribution tooltip
    Emerging biotech

    Pheon rides wave of ADC interest with $120M financing

    CEO Cyrus Mozayeni said the company is taking a different approach than other developers of antibody-drug conjugates, though it’s keeping details close.

    By May 21, 2024
  • An illustration of a neuron cell network on a black background.
    Image attribution tooltip
    koto_feja via Getty Images
    Image attribution tooltip

    Forbion-backed biotech Progentos debuts with $65M for MS drug

    Progentos says the money will go toward expanding its pipeline and pushing an experimental treatment for multiple sclerosis through "proof of concept” testing.

    By May 20, 2024
  • A stock photo of blocks arranged to illustrate layoffs
    Image attribution tooltip
    Andrii Yalanskyi via Getty Images
    Image attribution tooltip

    BIO to restructure, lay off staff in shakeup of lobbying group

    Thirty employees will leave as part of the reorganization, which the group said is meant to bring "stronger focus and greater impact" to its work.

    By May 20, 2024
  • Image attribution tooltip
    Elizabeth Regan / Industry Dive
    Image attribution tooltip

    Dyne shares jump on trial data for muscle disease drugs

    Updated study results for the biotech’s medicines for myotonic dystrophy Type 1 and Duchenne muscular dystrophy appeared to impress analysts and investors on Wall Street.

    By May 20, 2024
  • Image attribution tooltip
    Carl Court via Getty Images
    Image attribution tooltip

    European Commission, in ‘unprecedented’ move, declines to revoke approval of PTC Duchenne drug

    Rather than endorse the recommendation of the EMA, the commission called for a new review for Translarna that considers “the totality of the evidence” compiled to date.

    By May 20, 2024
  • Abstract
    Image attribution tooltip

    vitanovski/stock.adobe.com

    Image attribution tooltip
    Sponsored by IO Biotech

    Therapies designed to dismantle cancer’s escape mechanisms show promise for patients

    Hear from IO Biotech CEO Dr. Mai-Britt Zocca about the potential of therapeutic vaccines to strip the defenses used by cancer cells to keep the immune system at bay.

    By Mai-Britt Zocca, Ph.D., founder and chief executive officer, IO Biotech • May 20, 2024
  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Daniel Tadevosyan via Getty Images
    Image attribution tooltip
    News roundup

    Erasca restructures; Novartis moves to complete MorphoSys deal

    The cancer biotech is laying off one-fifth of its staff and scrapping three drugs. Elsewhere, Novartis secured sufficient support for its $3 billion buyout and Bristol Myers won a new CAR-T approval.

    By BioPharma Dive staff • May 17, 2024
  • Weight loss GLP-1
    Image attribution tooltip
    iStock via Getty Images
    Image attribution tooltip
    Obesity drugs

    Investors put $400M into biotech licensing obesity drugs from China

    The biotech, tentatively named Hercules CM Newco, has rights to three incretin drugs discovered by Jiangsu Hengrui Pharmaceuticals, two of which are in clinical testing.

    By May 16, 2024
  • A photo of a Biogen sign
    Image attribution tooltip
    Permission granted by Biogen
    Image attribution tooltip
    ALS drug development

    Biogen, Ionis shelve ALS drug following study failure

    While results indicated the drug works as intended, it didn’t have enough of an effect on a protein that’s become integral to many ALS research programs.

    By May 16, 2024
  • A blurred photo of an empty laboratory
    Image attribution tooltip
    Ozankutsal via Getty Images
    Image attribution tooltip

    Bolt Biotherapeutics to lay off staff, abandon lead ADC candidate

    The company will cut its workforce by half and shuffle leadership as it discontinues testing of the drug trastuzumab imbotolimod.

    By May 15, 2024
  • An illustration of human lungs with a geometrical effect.
    Image attribution tooltip
    eranicle via Getty Images
    Image attribution tooltip

    Blackstone-backed biotech launches with up to $300M for immune drug

    Uniquity Bio emerged from stealth mode ready to begin Phase 2 trials of an antibody targeting the protein TSLP in asthma and COPD.

    By Kristin Jensen • May 15, 2024
  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Daniel Tadevosyan via Getty Images
    Image attribution tooltip
    News roundup

    Novo Holdings buys stake in life sciences tools company; BioMarin lays off 170

    The parent of Novo Nordisk is acquiring 60% ownership of Single Use Support, which specializes in handling of advanced therapies. Elsewhere, BioMarin and gene therapy developer Tenaya are cutting jobs.

    By May 15, 2024
  • A man dressed in a suit looks at the camera in this headshot.
    Image attribution tooltip
    Permission granted by FogPharma
    Image attribution tooltip

    FogPharma, Artbio join forces to design a different radiopharma drug

    The biotechs aim to marry FogPharma’s polypeptide science with Artbio’s lead-based radiopharmaceutical technology in one of the industry’s hottest fields.

    By May 14, 2024
  • A clear drop with a dollar symbol is pipetted into a test tube.
    Image attribution tooltip
    ADragan via Getty Images
    Image attribution tooltip

    Sands Capital raises $555M fund amid upturn in biotech ‘crossover’ investing

    The firm, one of the sector’s more active crossover investors, closed the fund during a surge in the financings that bridge biotechs to the public markets.

    By May 14, 2024
  • A photo of Sanofi headquarters in Paris, France.
    Image attribution tooltip
    Courtesy of Sanofi
    Image attribution tooltip

    Sanofi gambles $80M on Fulcrum’s muscular dystrophy drug

    The deal gives the pharma partial rights to a medicine GSK once developed for heart disease but could soon become the first therapy for facioscapulohumeral muscular dystrophy.

    By May 13, 2024
  • An illustration of an inspection laboratory in a medicine production factory.
    Image attribution tooltip
    alvarez via Getty Images
    Image attribution tooltip
    Emerging biotech

    NewVale, an unorthodox investment firm, sets out to support biotech’s ‘infrastructure’

    The firm, which closed a $167 million fund, aims to fill a “crucial gap” by growing the companies startups turn to for outsourced services, founder Todd Holmes told BioPharma Dive. 

    By May 13, 2024
  • A man poses in a laboratory setting.
    Image attribution tooltip
    Permission granted by Ajax Therapeutics
    Image attribution tooltip
    Emerging biotech

    Ajax, aiming for a better JAK drug, raises $95M to begin first tests

    Goldman Sachs and Eli Lilly are among those backing the startup, which claims its prospect could be more potent than the myelofibrosis therapies that have come to market in recent years.  

    By May 13, 2024
  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Daniel Tadevosyan via Getty Images
    Image attribution tooltip
    News roundup

    iTeos shares jump on TIGIT update; Acelyrin swaps CEOs

    Interim data surpassed expectations, iTeos said. Bluebird bio, meanwhile, gave a fuller accounting of launch progress for its gene therapies Lygenia, Zynteglo and Skysona. 

    By BioPharma Dive staff • May 10, 2024
  • A composite image of two headshots, featuring Maze CEO Jason Coloma and CMO Harold Bernstein.
    Image attribution tooltip
    Permission granted by Maze Therapeutics
    Image attribution tooltip

    Maze lands new partner for Pompe drug, after Sanofi pact came apart

    An alliance with Shionogi involves similar terms as a deal Sanofi canceled in response to an unusual challenge from the Federal Trade Commission.

    By May 10, 2024
  • White flags bearing Novo Nordisk's logo are seen against a blue sky.
    Image attribution tooltip
    Courtesy of Novo Nordisk
    Image attribution tooltip
    Obesity drugs

    Novo taps another Flagship startup in search for next obesity drugs

    The deal with Metaphore Biotechnologies is the third from a Flagship alliance meant to boost the Danish drugmaker’s pipeline of weight loss medicines.

    By May 9, 2024